文献速递认知障碍与痴呆脑血管病

降压药类别与痴呆及认知下降关系的Meta分析

Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis.
PubMed 文献 · Neurology · 2019-12-11

该Meta分析纳入27项研究、超过5万名参与者,重新分析原始数据,比较不同降压药类别与未治疗或其他降压药治疗对痴呆和认知下降风险的影响。在65岁以上人群中,除利尿剂外,未发现各类降压药与认知结局存在明确关联,利尿剂的部分获益不一致。结论支持临床自由选择降压方案以实现血压目标。

要点

  • 65岁以上人群中,除利尿剂外,各类降压药与痴呆或认知下降风险无明确关联。
  • 利尿剂的获益信号不一致,受随访时间、对照组合和结局定义影响。
  • 现有证据支持为达到血压目标而自由选择降压药方案。

核心结论

  • 在65岁以上人群中,除利尿剂外,未发现特定降压药类别与痴呆或认知下降风险降低相关。
  • 利尿剂的部分分析提示获益,但结果在随访时间、对照组合和结局间不一致。
  • 当前证据支持临床自由选择降压方案以实现血压目标。

研究设计与样本

  • 纳入27项前瞻性纵向人类研究或降压药试验,超过50,000名参与者。
  • 结局为 incident dementia 或 incident cognitive decline,认知下降采用可靠变化指数法分类。
  • 数据按中年和晚年(>65岁)分层,每类降压药与未治疗及其他降压药治疗比较。
  • 综述注册于PROSPERO,注册号CRD42016045454。

主要发现

  • 65岁以上人群中,除利尿剂外,未发现各类降压药与 incident cognitive decline 或痴呆存在关联。
  • 利尿剂使用在某些分析中提示获益,但结果在随访时间、对照组合和结局间不一致。
  • 65岁及以下人群数据有限,无法进行有意义的分析。

临床怎么用

  • 对于65岁以上高血压患者,选择降压药类别时无需以预防痴呆或认知下降为主要依据。
  • 为实现血压目标,临床可自由选择降压药方案。
  • 利尿剂对认知的潜在获益证据不一致,不应作为优先选择该类药物的唯一理由。

局限性

  • 65岁及以下人群数据有限,无法进行有意义的分析。
  • 利尿剂相关结果在随访时间、对照组合和结局间不一致。
  • 原文未报告纳入研究的异质性或偏倚风险评估细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: High blood pressure is one of the main modifiable risk factors for dementia. However, there is conflicting evidence regarding the best antihypertensive class for optimizing cognition. Our objective was to determine whether any particular antihypertensive class was associated with a reduced risk of cognitive decline or dementia using comprehensive meta-analysis including reanalysis of original participant data. METHODS: To identify suitable studies, MEDLINE, Embase, and PsycINFO and preexisting study consortia were searched from inception to December 2017. Authors of prospective longitudinal human studies or trials of antihypertensives were contacted for data sharing and collaboration. Outcome measures were incident dementia or incident cognitive decline (classified using the reliable change index method). Data were separated into mid and late-life (>65 years) and each antihypertensive class was compared to no treatment and to treatment with other antihypertensives. Meta-analysis was used to synthesize data. RESULTS: Over 50,000 participants from 27 studies were included. Among those aged >65 years, with the exception of diuretics, we found no relationship by class with incident cognitive decline or dementia. Diuretic use was suggestive of benefit in some analyses but results were not consistent across follow-up time, comparator group, and outcome. Limited data precluded meaningful analyses in those ≤65 years of age. CONCLUSION: Our findings, drawn from the current evidence base, support clinical freedom in the selection of antihypertensive regimens to achieve blood pressure goals. CLINICAL TRIALS REGISTRATION: The review was registered with the international prospective register of systematic reviews (PROSPERO), registration number CRD42016045454.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Peters R, Yasar S, Anderson CS, et al. Investigation of antihypertensive class, dementia, and cognitive decline: A meta-analysis. Neurology. 2019. PMID: 31827004. doi:10.1212/WNL.0000000000008732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。